Market Strategist believes the stronger economy needed for rate hike will provide tailwind for corporate profits» Read More
The daily White House press briefing ended abruptly after a Secret Service officer announced that the briefing room needed to be evacuated.
White House press briefing room has been evacuated. CNBC's Eamon Javers reports the latest.
Jeff Rosenberg, BlackRock, is not surprised by the huge move in yields and discusses where investors should go.
The Reverend Franklin Graham is calling on Christians to boycott corporations that promote homosexuality. CNBC's Hampton Pearson reports.
According to Bankrate's new list of best cities to retire, Arizona is the place to be, reports CNBC's Sharon Epperson.
Where the happiest workers are, with CNBC.com's Eric Chemi and Ari Levy.
CNBC's Scott Cohn crunches the numbers on government subsidies.
The play on current market conditions, with Dave Donabedian, Atlantic Trust, and Brian Peery, Hennessy Funds.
John Kosar, Asbury Research, looks at the charts to see where oil might be headed.
CNBC's Mary Thompson and Roger Hochschild, Discover Financial Services president and COO, discuss the state of the consumer and student loan risks.
Discussing the safety of America's airports, with CNBC's Eamon Javers and Robert Crandall, former American Airlines chairman and CEO.
Alibaba's Jack Ma spoke on entering the U.S. market. Details, with CNBC's Josh Lipton.
Discussing added capacity and slashed prices in the airline space, with Robert Crandall, American Airlines former chairman and CEO.
Crandall slams air marshal program, calls for it to be eliminated.
Time to buy consumer discretionary stocks.
Bankrate names its best and worst cities for retirement based on cost of living, crime, health care and taxes.
Chart analyst John Kosar provides historical context on the price of oil in order to find where it may be headed next.
Time to buy China? A look at MSCI's expected announcement, with CNBC's Bob Pisani.
CNBC's Dominic Chu breaks down the latest 3-Year Treasury note auction results.
CNBC's Meg Tirrell reports on a FDA panel considering whether to approve the first in a new class of drugs many experts believe could cut the risk of heart attacks and strokes.